BIZENGRI

(Zenocutuzumab)

Phase 2Monoclonal antibody

MMerus B.V.

BIZENGRI is one of 47 small molecule programs targeting Patients With Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Patients With Solid TumorsActive, not recruiting

Patients With Solid TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

68 competitors in Patients With Solid Tumors

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

13 2

Faslodex

FFresenius Kabi USA, LLC

Phase 3

2 3

Keytruda

Merck & Co.

Phase 2

6 4

Avastin

Roche

Phase 2

6 5

Opdivo

Bristol-Myers Squibb

Phase 2

5 6

Imfinzi

AstraZeneca

Phase 2

3 7

Eloxatin

Teva

Phase 2

2 8

Lynparza

AstraZeneca

Phase 2

1 9

Mektovi

Pfizer

Phase 2

1 10

Pemazyre

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Patients With Solid Tumors

NCT02912949

Clinical

Trials by Indication[1]

Breast Cancer1 trial

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Completed·MMerus B.V.·Phase 2·NCT03321981·105 enrolled

Patients With Solid Tumors1 trial

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Active, not recruiting·PPartner Therapeutics, Inc.·Phase 2·NCT02912949·250 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 4, 2024

BIZENGRI

BLA BLA761352

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Zenocutuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zenocutuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zenocutuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761352). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Merus B.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: MMerus B.V.

BIZENGRI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer1 trial

Patients With Solid Tumors1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News